AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ 2024 Deloitte Technology Fast 500™ Ranks AscellaHealth Number 154 with 753% Revenue Growth